BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

...ASA Molecular Partners AG Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1) CD28 Inducible T cell co-stimulator (ICOS) CC chemokine receptor 5 (CCR5) (CD195) Melanoma...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
BioCentury | Aug 15, 2020
Product Development

Celltrion launches antigen and serology COVID-19 tests in the U.S., Verily adds capacity with CLIA lab and more

...from the Phase II CD10 study. The anti-CCR5...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

...a broad immunosuppressant, and target different biological mechanisms associated with ARDS. Cenicriviroc is a dual CCR2/CCR5...
...B2R) - Bradykinin B2 receptor CCR2 (CD192) - CC chemokine receptor 2 CCR5 (CD195) - CC chemokine receptor 5...
...Inc. AbbVie Inc. Quantum Leap Healthcare Collaborative Bradykinin B2 receptor (BDKRB2) (B2R) CC chemokine receptor 2 (CCR2) (CD192) CC chemokine receptor 5 (CCR5) (CD195) Tyrosine...
BioCentury | Jul 16, 2020
Regulation

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

...in highly treatment experienced HIV patients. The company said no additional trials are required. The CCR5...
...the anti-VEGF mAb plus the chemotherapies -- are not yet mature. Targets CCR5 (CD195) - CC chemokine receptor 5...
...#), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) CytoDyn Inc. Johnson & Johnson Alnylam Pharmaceuticals Inc. Verrica Pharmaceuticals Inc. Roche CC chemokine receptor 5 (CCR5) (CD195) Interleukin-23...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...trials, the first of which will test three host-targeted immune modulators against TNFα, CTLA-4 and CCR2/CCR5...
...Phase I safety studies. Targets CCR2 (CD192) - CC chemokine receptor 2 CCR5 (CD195) - CC chemokine receptor 5...
BioCentury | Jun 13, 2020
Product Development

ACTIV coming into focus, starting COVID-19 therapy trials in June

...a diagnosis of COVID-19. It will test three host-targeted immune modulators against TNFα, CTLA-4 and CCR2/CCR5...
...lungs and leads to ARDS (acute respiratory distress syndrome). While the chemokine receptors CCR2 and CCR5...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...The company has treated 12 mild-to-moderate COVID-19 patients in a Phase II trial of its CCR5...
BioCentury | Apr 14, 2020
Deals

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a...
Items per page:
1 - 10 of 937